Q3 2023 Cytokinetics Inc Earnings Call
Participants
Andrew M. Callos; Executive VP & Chief Commercial Officer; Cytokinetics, Incorporated
Ching W. Jaw; Senior VP & CFO; Cytokinetics, Incorporated
Diane Weiser; SVP of Corporate Communications & IR; Cytokinetics, Incorporated
Fady Ibraham Malik; EVP of Research & Development; Cytokinetics, Incorporated
Robert C. Wong; VP & CAO; Cytokinetics, Incorporated
Robert I. Blum; CEO, President & Director; Cytokinetics, Incorporated
Stuart Kupfer; Senior VP & Chief Medical Officer; Cytokinetics, Incorporated
Charles Cliff Duncan; Research Analyst; Cantor Fitzgerald & Co., Research Division
Dane Vincent Leone; MD & Biotechnology Analyst; Raymond James & Associates, Inc., Research Division
Fatima Amanat; Associate Director of Biopharmaceuticals; UBS Investment Bank, Research Division
Hannah Lynne Latimer; Former Research Associate; Morgan Stanley, Research Division
Jason Nicholas Butler; MD, Director of Healthcare Research & Equity Research Analyst; JMP Securities LLC, Research Division
Joseph Pantginis; Director of Research & MD of Equity Research; H.C. Wainwright & Co, LLC, Research Division
Justin Alexander Kim; Associate; Oppenheimer & Co. Inc., Research Division
Roanna Clarissa H. Ruiz; Director of Infectious Disease, Endocrine & Cardiovascular Disorders & Senior Research Analyst; Leerink Partners LLC, Research Division
Salim Qader Syed; MD, Senior Biotechnology Analyst of Equity Research & Head of Biotechnology Research; Mizuho Securities USA LLC, Research Division
Serge D. Belanger; Senior Analyst; Needham & Company, LLC, Research Division
Srikripa Devarakonda; Associate; Truist Securities, Inc., Research Division
Unidentified Analyst
Yasmeen Rahimi; MD & Senior Research Analyst; Piper Sandler & Co., Research Division
Presentation
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Third Quarter 2020 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I would now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D, will provide updates related to aficamten focused to SEQUOIA-HCM and FOREST-HCM. Stuart Kupfer, SVP and Chief Medical Officer, will provide additional updates for aficamten relating to ACACIA-HCM and MAPLE-HCM and will also discuss our early-stage pipeline, inclusive of CK-586 and CK-136.
Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness activities for aficamten. Robert Wong, VP and Chief Accounting Officer, will provide a financial overview of the past quarter and Ching Jaw, SVP and Chief Financial Officer, will discuss our financial outlook and corporate development strategies. And finally, Robert Blum will provide closing comments and review upcoming expected key milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.
Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our third quarter 2023 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.
And now I will turn the call over to Robert.
Robert I. Blum
Thank you, Diane, and thanks for joining us on the call today. I'm pleased with the progress we made in the third quarter, particularly focused to aficamten our top priority and with emphasis on the execution of SEQUOIA HCM and advancement of its broad development program. Thanks to the diligence and dedication of our teams, we remain on track to share top line results from SEQUOIA HCM in late December.
While this time line is admittedly tight, we're confident due to the superb organization and oversight of SEQUOIA HCM by our clinical operations and statistical teams, like all of you on the call, we're eager to see these top line results. As Fady will elaborate, we have strong conviction that the top line results from SEQUOIA HCM will meet our high expectations for both safety and efficacy based on the patient population enrolled in SEQUOIA HCM as well as the unique attributes of aficamten.
If SEQUOIA HCM meets our expectations on both efficacy and safety, we expect it may contribute to expansion of the cardiac myosin inhibitor or CMI category on both accounts. Simultaneously, during the quarter, we continued to build our specialty cardiology franchise by advancing the ongoing clinical trials in the development program for aficamten as well as earlier-stage clinical research with enrollment underway in both MAPLE HCM and ACACIA-HCM, we foresee a near-term future with multiple catalysts for aficamten.
And rounding out our specialty cardiology franchise, our CK-586, a second cardiac myosin inhibitor and CK-136, a cardiac troponin activator, on which Stuart will provide an update. Our cash position at the end of the quarter represents over 18 months of cash runway based on our 2023 net cash burn guidance.
Importantly, as is our practice for both financial health and prudent planning, we're gating spending through the readout of top line results of SEQUOIA HCM, and we're judiciously focusing our current spending on activities related to our top priorities, again, with focus to aficamten and a critical eye towards cost efficiencies.
Today, you'll hear about the continued progress we made during the quarter and what to expect through the end of the year as we approach 2024, and as you heard a few weeks ago at our Investor and Analyst Day, Cytokinetics remains laser focused to delivering on the promise of aficamten as well as to advancing our earlier-stage pipeline as we build our specialty cardiology franchise for the potential benefit of both patients and shareholders.
And with that, I'll turn the call over to Fady.
Fady Ibraham Malik
Thanks, Robert. In the third quarter, we made significant headway across the development program for aficamten. Recently, we were pleased to present the baseline characteristics of patients enrolled in SEQUOIA HCM, the pivotal Phase III clinical trial of aficamten at the HCM Society Scientific Sessions. The baseline characteristics met our objective for the intended trial population, having enrolled a global, diverse and real-world population with a substantial deficit in exercise capacity and significant symptom burden despite existing standard of care.
Patients enrolled in SEQUOIA HCM had an average peak oxygen uptake or peak VO2 of 18.5 milliliters per kilogram per minute at baseline or 56.9% of that predicted for their age and sex, which is an objective indicator of the extent of their reduced exercise capacity. Nearly 1/4 of the patients were NYHA functional class III with an average KCCQ score of 74.7 further reflective of a highly symptomatic patient population despite background treatment with guideline-directed medical therapies.
Background medical therapy included beta blockers, calcium channel blockers and disopyramide with patients permitted to receive combination background medical therapy. Beta blockers, which were known the blunt maximum exercise capacity due to their effect to slow heart rate we used in 61% of the patients. We are very pleased to see that our objectives are achieved and that we enrolled the population that we intended.
As we approach the readout of SEQUOIA-HCM later this year, we're confident in the completeness of the data and that we're outperforming the design assumptions for the trial. The extent of missing data and the standard deviation of the primary endpoint are all within our assumptions, which should augment the power of the trial to assess the change in the primary end point. I'm also pleased to report that nearly all patients have completed dosing and sites have not reported any patients with an LV ejection fraction less than 40%.
We're eagerly anticipating sharing the top line results in late December. Our convictions are high that the results of SEQUOIA-HCM will meet our expectations. These convictions are further reinforced by the long-term efficacy and safety of aficamten that we're observing in FOREST-HCM, the open-label extension clinical trial. At our recent Investor and Analyst Day, we shared new longer-term data with data available in some patients for greater than 2 years.
More than 200 patients have been enrolled in FOREST-HCM to-date and data from 143 patients with obstructive HCM were available for this analysis. The new data from FOREST-HCM showed that no patient had a treatment-related LV ejection fraction less than 50% during the treatment period -- during the titration period and approximately 2/3 are receiving 15 milligrams or 20 milligrams of aficamten.
During the maintenance phase of FOREST-HCM, there have been no instances of LVEF plus with 40%, which would require treatment interruption and only 3 instances of LVEF less than 50% that simply required a dose down titration. Of the 579 monitoring echocardiograms completed during the maintenance phase of treatment, 99.5% of them did not result in a dose down titration. We also observed in these reported data from FOREST-HCM that the mean resting and 00:09:24 [LVOT] gradients remain reduced and below the diagnostic threshold for obstructive HCM after treatment for more than 2 years.
Patients also experienced sustained reductions in cardiac biomarkers and improved symptoms. Approximately half of patients were NYHA functional class I or asymptomatic and 80% of patients improved by one or more functional class. Furthermore, 90% of the SCT eligible patients at baseline were no longer SCT eligible at the time of this analysis. aficamten has been generally well tolerated with no treatment-related serious adverse events as assessed by investigators.
Additionally, approximately 30% of patients have reduced doses of background therapy are discontinued entirely at the discretion of the treating physician and/or by request from the patient. This supports the rationale for MAPLE-HCM, which Stuart will discuss next. These new results from FOREST-HCM are quite compelling, and we look forward to continuing to gather more longer-term data for aficamten in this open-label extension.
Shifting briefly back to SEQUOIA-HCM, following the top line readout of the results in late December, we expect to hold a meeting with FDA in the first quarter of next year to discuss the top line results with the goal of potentially submitting a new drug application for aficamten in the second half of 2024.
During that initial meeting to review the top line results, we'd expect to begin a dialogue about how do the safety and efficacy of aficamten observed in REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM would influence the design of a REMS program. We look forward to these interactions and we'll provide further updates next year.
Now I'll hand it over to Stuart to elaborate on additional progress we made for aficamten and provide an update on our earlier-stage clinical pipeline.
Stuart Kupfer
Thanks, Fady. During the third quarter, we started ACACIA-HCM, a pivotal Phase III clinical trial of aficamten in patients with symptomatic nonobstructive HCM. Enthusiasm among investigators as high as many of the investigators participating in ACACIA-HCM have prior experience with aficamten from REDWOOD-HCM, FOREST-HCM and SEQUOIA-HCM.
Additionally, as you may know, patients with nonobstructive HCM have limited treatment options. Standard of care medications, including beta blockers and calcium channel blockers are not very effective, and therefore, patients with nonobstructive HCM often struggle with a high symptom burden. Our hope for this clinical trial is to gather evidence about the potential of aficamten for this important segment of the HCM population, which lacks treatment option.
In the third quarter, we also continued patient enrollment in MAPLE-HCM, the Phase III clinical trial, evaluating for the potential superiority of aficamten with monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM. We're pleased to report that enrollment is progressing according to plan. If positive, MAPLE-HCM should support the possibility for aficamten to be considered for first-line therapy in obstructive HCM.
Shifting to our earlier stage pipeline. As Robert mentioned, we also made progress advancing both CK-586 and CK-136 during the quarter. We've now completed the single-dose cohorts of the healthy participants in the Phase I study of CK-586, our cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with heart failure with preserved ejection fraction, or HFpEF with hypercontractility.
We've now concluded our analyses of the single-dose cohorts, which are supportive of the proceeding to the multiple dose portion of the study, which we expect to start in this fourth quarter. As the Phase I study progresses, we also recently unveiled new preclinical data for CK-586 at our Investor and Analyst Day, showing improved diastolic function and reduced cardiac fibrosis in an animal model of HFpEF. These data, along with the results observed with aficamten in nonobstructive HCM, which has features similar to that of HFpEF with hypercontractility support the potential benefit of CK-586 in this patient population.
Shifting to CK-136, our cardiac troponin activator, we completed the single ascending dose cohorts in the Phase I study in healthy participants. And we're now analyzing these data to inform potentially proceeding to the multiple dose cohorts of the Phase I study.
With that, I'll turn the call over to Andrew.
Andrew M. Callos
Thanks, Stuart. As we outlined at our Investor and Analyst Day, our approach to commercial readiness in 2023 is centered around understanding the patient journey and the holistic experience of living with HCM. As such, we have been focused on gaining a deep understanding of the HCM market with the intention of designing an optimal physician and patient experience.
During the quarter, we continued to conduct market research to assess potential patient profiles and available market segments in obstructive HCM, which have confirmed the symptomatic patient population in need of disease-modifying treatment with a potential next-in-class CMI. By anchoring our commercial strategies to this patient-centric approach, we are preparing to address a high unmet customer need with the objective of positively impacting patients and shareholders if aficamten is approved.
At the same time, we're learning through our market research that physicians indicate a strong interest in the potential target product profile for aficamten showing that there is room to capture CRM share among newly treated HCM patients and the potential to expand the total CMI market.
Furthermore, we expect CMI penetration of eligible -- obstructive HCM patients to be less than 20% at the time of expected launch of aficamten, meaning that over 80% of the obstructive HCM eligible patient population will remain untreated with the CMI. We are, therefore, focusing our commercial readiness strategies to those enabling expanded use of CMIs, building on the expected next-in-class profile about the aficamten arriving from our clinical trials program.
We also will strive to design a seamless and patient-friendly CMI experience through a comprehensive patient support program to help address the emotional, financial and educational needs of a patient throughout their journey. With the patient experience in mind, we recently held a mystery theater program at the HFSA Annual Scientific Meeting where we facilitated a discussion surrounding the impact of obstructive HCM, which may have a -- patient quality of life, metal health and well-being as well as how cardiologists can better understand and address these concerns.
This approach of elevating the holistic and human-centric view of HCM is resonating with HCP's and -- we hope it may help foster better physician-patient conversations and raise more awareness of the myriad impact of [kin]. Through the end of the year, we plan to continue our market research and go-to-market planning for aficamten. In 2024, our experienced team will shift focus to the design and build of our commercialization strategies as informed by market research, the results of SEQUOIA-HCM and our deepening market insights.
With that, I'll turn the call over to Robert Wong.
Robert C. Wong
Thanks, Andrew. We ended the third quarter with $554.7 million in cash and investments. During the quarter, we received a $50 million milestone payment from Royalty Pharma upon the start of ACACIA-HCM, which is treated as a liability on our balance sheet in accordance with GAAP.
In addition, recently, we received a $2.5 million milestone payment from Ji Xing received upon the start of ACACIA-HCM. Our third quarter 2023, R&D expenses increased to $82.5 million from $62.7 million in the third quarter of 2022, primarily due to spending on our cardiac myosin inhibition programs. Our third quarter 2023 G&A expenses were $40.1 million, down from $48.2 million in Q3 2022, due primarily to lower outside service spending.
Now I'll hand it over to Ching to review our financial outlook and corporate development strategy.
Ching W. Jaw
Thanks, Robert. As Robert mentioned, we ended the quarter with approximately $555 million on the balance sheet, which represents over 18 months of cash runway based on our 2023 net cash burn guidance. In the second half of the year, we have reduced our spending and are critically assessing our go-forward spending priorities to help facilitate the best return on our financial commitments.
Our main priority remains aficamten and as we approach 2024, we are being prudent in our spending around preparations for the potential commercial launch of aficamten. Towards that end, we are gaining expenses ahead of our sharing the top line results of SEQUOIA-HCM. Once we have the results and provided they are positive, we will be able to refine our assumptions further and on [gate] spending.
As usual, we plan to provide guidance to our 2024 spending during the Q4 earnings call. As for access to capital, I'll remind you that through our transaction with Royalty Pharma, we remain eligible for 2 additional loan tranches under our development funding agreement, including $75 million upon our potentially sharing positive results from SEQUOIA-HCM and $100 million upon acceptance of an NDA submission for aficamten in the U.S.
As it relates to corporate development, over the year, we have engaged in a rigorous process in which we met with multiple potential partners. We have noted a high degree of interest in aficamten, both independently and in some cases, in concert with potential to include omecamtiv mecarbil in regions outside of North America. This process has affirmed the value proposition to our go to Europe strategies.
With that said, we do not expect to enter into a partnering deal prior to announcing the top line results from SEQUOIA-HCM, and we'll continue to evaluate how we access and deploy capital as we will learn more about aficamten from SEQUOIA-HCM.
Now I will turn the call back to Robert Blum.
Robert I. Blum
Thank you, Ching. As we proceed to close out 2023, we're approaching an important inflection point for our company. With aficamten representing the leading edge of our specialty cardiology franchise, the top line results from SEQUOIA-HCM will potentially accelerate our momentum as we plan transitions to become a fully integrated biopharmaceutical company in 2024.
In 2023, much was put into motion that is now carrying us closer to our goal of bringing forward new medicines for patients with diseases of impaired muscle function. While our priority remains aficamten and our earlier-stage pipeline, during the quarter, we submitted a formal dispute resolution request to the FDA's Office of New Drugs regarding the CRL or complete response letter for omecamtiv mecarbil.
Our objective is to appeal FDA's conclusion that substantial evidence of effectiveness has not been established to support approval of omecamtiv mecarbil. As I've said before, we do not currently have plans to conduct another clinical trial of omecamtiv mecarbil, and we may not be able to address the deficiencies noted in the CRL. However, we still believe in the science underlying omecamtiv mecarbil and the demonstrated evidence to potentially benefit patients with advanced or worsening heart failure.
If our appeal to FDA proves successful, we'll then consider potential next steps for omecamtiv mecarbil, albeit and importantly, as to the lens of a company for which our top priority is aficamten. We also continue to pursue potential approval for omecamtiv mecarbil outside of the U.S.
Regarding Europe, we submitted our responses to the day 120 questions to the EMA and now await their feedback. As it relates to China, our partner, Ji Xing, submitted a request for voluntary withdrawal of the NDA for omecamtiv mecarbil to the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China, subject to potential resubmission upon received a favorable feedback from EMA or FDA with regard to potential drug approval for omecamtiv mecarbil in the EU or U.S., respectively.
Shifting now to business development. As Ching said and to be clear, we do not expect to partner aficamten leading into the readout of SEQUOIA-HCM. Our focus remains on that, which is under our control and that which is the most meaningful for our company and for patients and shareholders, which is advancing aficamten. However, it is reinforcing to our corporate strategies to have engaged with potential partners who have expressed a high level of interest in aficamten and ultimately validate our own planning.
We believe that we are doing right by all of our stakeholders to objectively and critically evaluate our own plans. As a result, with the readout of results from SEQUOIA-HCM, we'll be better prepared to execute on our strategies.
As we approach the end of 2023, we reflect on a year marked with both ups and downs admittedly. We have faced certain setbacks which tested our company's grit and resilience, but we've also made great progress. Today, we're uniquely positioned for success with a strong specialty cardiology franchise led by our own broad late-stage development program for aficamten complemented by earlier-stage drug candidates that have arisen from our industry-leading research and leadership in muscle biology and the mechanics of contractility.
That plus our relationships with key stakeholders and our access to capital sets us apart as does our passion, our dedication to our mission and our focus on doing right by patients. I look forward to 2024 with optimism and eager anticipation for what's yet to come. Lastly, and before I recap our upcoming milestones, I'd like to also mention that leading into the results and the readout of SEQUOIA top line in late December, we plan to enter a quiet period starting on Monday, December 4.
Now our upcoming milestones. For aficamten, we expect to share top line results from SEQUOIA-HCM in late December and continuing enrollment of patients in MAPLE-HCM and ACACIA-HCM and continue to advance our go-to-market strategies for aficamten. For omecamtiv mecarbil, we expect to continue to pursue potential approval for omecamtiv mecarbil in Europe.
And for CK-136, we expect to analyze data from the single ascending dose cohorts of the Phase I study to inform potentially proceeding to the multiple ascending dose cohorts in that Phase I study. And finally, for CK-586, we expect to proceed to the multiple ascending dose cohorts in that Phase I study in this quarter, Q4 2023.
Operator, with that, we can now open up the call to questions, please.
Question and Answer Session
Operator
(Operator Instructions) And our first question will come from Joe Pantginis from H.C. Wainwright.
Joseph Pantginis
So curious on Fady's comments with regard to the patient populations in SEQUOIA. And specifically, any more color you could provide with regard to the background therapy reductions and more importantly, how these therapy reductions might improve the quality of life and the safety of these patients? And then secondly, just quickly, anything meaningful to discuss with regard to the cost impacts of the formal dispute with the FDA and the EMA filings for omecamtiv?
Robert I. Blum
Sure. I'll let Fady answer your first question, and I'll take the second.
Fady Ibraham Malik
Thanks, Joe. I think with regard to withdrawal of background therapy, the protocol, as we reported back at ACC allows investigators to slowly withdraw beta blockers or other background therapies such as disopyramide or calcium channel blockers based on patient tolerance. And then at the same time, they're also allowed to up-titrate aficamten as necessary to compensate.
And so we see -- I can't give you exact percentages, but we see a substantial, about 2/3, I think, withdraw from all background therapy. I think in most cases, they've been able to discontinue disopyramide and also with beta blockers as well quite successful in terms of withdrawing from those. So I think from a patient point of view, it simplifies medical therapy. It gets them off of some of the troublesome adverse events that they experience with those drugs and it simplifies their medical regimen.
Robert I. Blum
And to your second question regarding potential costs associated with our submitting the formal dispute resolution, they're really quite minimal. These are costs that relate to internal activities and together with counsel, no new studies, no new analyses, nothing that would represent a meaningful investment of spending.
Operator
And our next question will come from Dane Leone from RJS.
Dane Vincent Leone
Yes, we're talking a lot lately. So really only one question from me that keeps coming up with investors is given the late December nature of the top line of SEQUOIA. Can you just provide any detail of how you think the team will handle disclosure of the top line data? I think a lot of people point back to some of the early REDWOOD disclosures that your team made around a description of some of the key primary endpoints and maybe some detail around left ventricular ejection fraction, adverse events. But anything you can tell us of how your team plans to handle I think, could be really helpful for seeing expectations?
Robert I. Blum
Sure. I'll do my best, recognizing that we don't have the data, so it's hard to be as clear as you might want us to be. But our goal is to disclose all of that, which should hopefully convey our ability to have achieved a next-in-class potentially best-in-class profile for aficamten.
How much of that will be quantitative with p-values, primary and secondary endpoints, safety and adverse effects is ultimately going to depend on that which we can consider alongside of, hopefully, the American College of Cardiology, where we would hope to be presenting these data, albeit not for several more months afterwards.
So our goal will be to be communicative as much as we can, but knowing we don't want to jeopardize any presentation at a proper scientific forum. So, we recognize what is expected, if we're going to have a next-in-class potentially best-in-class profile. And those are the things that are top of mind for us as we will think about that, which we can disclose. Obviously, we've got to disclose that, which is deemed material to shareholders.
Operator
Our next question will come from Salim Syed from Mizuho.
Salim Qader Syed
I guess a question from me. I'll just follow-up on that on SEQUOIA. I just wanted to maybe hear from you or Fady, just so that we are all clear on how we should compare mavacamten to aficamten? [They had a 1.4% 00:32:56 change unit change on peak] VO2, and I think there was about a 6% injection fraction sub-50%. Just curious if you could just frame work for us the bookends, low end and high end on peak VO2. Like is it a 1 point change in a 1.8 where it'd be comparable? Or where do you actually start to feel like you can differentiate on efficacy. And the same question just on safety, how much different do you need to be versus mavacamten in order to feel like you can actually differentiate and how that speaks to our REMS, et cetera?
Robert I. Blum
Sure, Salim. So you won't be surprised for me to again emphasize that we're not going to be making comparative statements with mavacamten. The SEQUOIA-HCM study is a different study than was the study, EXPLORER-HCM that led to the approval of mavacamten. All I can speak to and all Fady will speak to is that which relates to aficampten and what our expectations are, ultimately, labeling and positioning and how physicians see those two potential medicines will define what will be our hope of expanding the category and best-in-class. So with that long caveat, maybe I'll ask Fady to try his best to speak to what our expectations are around aficampten in SEQUOIA-HCM.
Fady Ibraham Malik
Yes. Salim, I think what we will see and hope to see is that the changes are going to be meaningful in magnitude, such that the question isn't really one of whether there's a slight difference between one or the other. Both drugs are going to be -- well, I should say mavacamten, we know is quite effective in patients. We hope to see aficampten be equally or even better effective.
I don't think you can judge those types of things just based on comparisons of a single number. You have to really look at the totality of the data across all the endpoints. You have to couple it with the safety profile as again, as we might see in the study. And so there's not a simple answer to your question, as I know you're hoping me to provide.
Operator
Our next question will come from Jason Zemansky from BofA.
Unidentified Analyst
This is [Cameron Rosa] from Bank of America Securities on for Jason Zemansky. Congratulations on the progress, I'd like to ask a follow-up on EF, if I may. You recently reported data from FOREST-HCM OLE, where 3 patients had an LVEF production below 50%. What do you think you need to show regarding LVEF productions in SEQUOIA to make regulators comfortable permitting fewer echos as part of a potential REMS that have to fall below EXPLORER 6% or following the death in MAPLE EXPLORER are regulators to be more cautious on the class as a whole, at least initially?
Robert I. Blum
Sure. And thank you for the question. I've read some of the research that you guys have published relating to this matter, and maybe I could clarify how we think about it. We're looking at data from SEQUOIA-HCM with already having discussed with FDA in the design of SEQUOIA-HCM, a protocol that's permitting of down titrations when EF falls below 50% as opposed to dose interruption or dose termination.
The consequences of down-titration being well within the norm of cardiology group practices in this area. So, we approach the data when it will be available from SEQUOIA-HCM with those same optics, meaning I don't think it's really a question of its 3% or 6% or any number within that range. But how does that really affect patients and physicians? And how likely would FDA feel about what would be the consequence if EF does fall.
We're feeling emboldened by the fact that aficamten has a half-life that's enabling of a relatively rapid return to normalcy with an EF such that if EF does drop, it may be inconsequential. And in that way, a simple down titration would be acceptable by physicians without any concerns and worry. We believe that could be very important for ultimately the profile of aficamten.
So I wouldn't dwell on the number. Even though, as Fady reported, we've had quite a low number of EF excursions and 99.5% of echos have not resulted in any adjustment to dose, but for the fact that these down titrations might occur occasionally, I would think that, that will go a long way to be providing, hopefully, if the data in SEQUOIA bear out like we've seen in FOREST, a profile that will be deemed next in class. Fady, anything you want to add to that?
Fady Ibraham Malik
I just might add that cardiologists are really quite adapt at managing drugs that have to be monitored. And if you think about, for instance, heart failure therapies like mineralocorticoid receptor antagonist -- these drugs have long been known to cause rises in potassium even life threatening increases in potassium. And if you read the label of eplerenone, for instance, in 1% to 4% patients that receive these drugs.
And it's not -- cardiologist no stranger to drugs that need to be monitored. So I don't think it's -- ultimately, as one becomes familiar with a class that it's not surprising that one begins to see monitoring become changing over time and it becomes as part of standard practice. So I think as Robert said, what we've seen to date with aficamten, coupled with familiarity with the class would hopefully lead to something that's both reasonable for patients and physicians to execute and maintain patient safety
Operator
Our next question comes from Serge Belanger from Needham.
Serge D. Belanger
A follow-up on a prior question regarding the data disclosure that we're expecting in late December. ACC has historically been pretty restrictive and what can be disclosed ahead of the late-breaking clinical trial presentation at their meeting. So in some cases, we heard nothing more than whether at a primary endpoint. So just curious if you're confident that you will be allowed to provide more data than that on both the efficacy and the safety side of the trial?
Robert I. Blum
Thank you. Again, not having the data, it's difficult to be as clear as you might ultimately want. But yes, I'm confident I think we can communicate what we need to communicate, to be satisfying both our objectives to be disclosing that, which is deemed material for the benefit of shareholders and ultimately also enabling of a proper presentation at the ACC when it comes. We've been down this path before. Others have to. And I think this is something that can be accomplished.
Operator
Our next question will come from Ashwani Verma from UBS.
Fatima Amanat
Fatima here on behalf of Ash Verma from UBS. Just two quick ones here. We understand that you have low beta blocker use in your study from the baseline characteristics. And that can help tease out the effect size for aficamten. But since data blocker usage is really high in the real world, with aficamten effect size in real world potentially be lower than what you will show in the SEQUOIA study. I mean just a second quick one. We want to get your views on what is the relationship between LVOT it was great in reduction and peak VO2. We have some studies like one from [KEMZYO] that shows correlation, but there are other studies from beta blockers that show that there is no correlation. So what do you see as the posality or the correlation between these two end points when it comes to aficamten?
Robert I. Blum
Sure. So I'll just start and then ask Fady to speak to your questions. We designed and conducted a study SEQUOIA-HCM that we believe is very representative of the population that we hope ultimately aficamten will be available to treat. So it's not an artificial construct. It's not a manufactured population. It's in fact, real world. And in that way, we went to great pains to ensure that this was a study that was enabling of physicians ultimately upon the availability of data to apply these results to their own practices. And with that, I'll turn it to Fady.
Fady Ibraham Malik
Yes. Let me remind you that I said 61% of the majority of patients are taking beta blockers. It's not out of line with what it's seen in the real world. Additionally, you look at the use of calcium channel blockers, the allowance for combination therapy of calcium channel blockers and beta blockers or beta blockers and dicoparamide. I would argue that SEQUOIA-HCM provides a very relevant real-world experience in terms of aficamten's effectiveness when we have those data.
So I think that question is really answered by the baseline characteristics. It showed that there's a high degree of background medical therapy that's employed. I think the second point, as we pointed out, is that background therapy may not be optimal for these patients. Ultimately, some of these background therapies may be holding them back and beta blockers being an example.
One of the reasons you see less good correlations between LVOT gradient reduction and peak VO2 is, because beta blockers disrupt that correlation in the absence of being able to increase your heart rate during exercise, even as you've gotten rid of the gradient, you can increase your exercise performance, because you can increase your heart rate. And so, it's more complicated, unfortunately, than a clean scientific experiment where you change one variable and measure another variable.
But roughly, there is a good correlation -- reducing the gradient has always been the target of both medical and surgical therapy. And obviously, there's precedent in the class that reducing the gradient improves PVO2.
Operator
And our next question will come from Jason Butler from JMP Securities.
Jason Nicholas Butler
Just wondering if you could comment on, from a commercial planning perspective, how feedback from FDA, assuming positive data from SEQUOIA and you meet with FDA in 1Q, '24. How that feedback on a REMS program will impact your commercial planning and scenario there, the REMS could be similar to mavacamten or less burdensome the mavacamten?
Robert I. Blum
So I just want to make sure I captured your question properly. Could you repeat the first part?
Jason Nicholas Butler
Yes. Just when you get feedback from FDA on potential of what a REMS program may look like, how that would impact your commercial planning in scenarios where the REMS was similar to mavacamten or less burdensome the mavacamten?
Robert I. Blum
Okay. No, I understand. Thank you. I'm going to ask Andrew to speak to some of this, but please understand that absent the data, right now, these are abstract scenarios that we've contemplated in market research. And once we have the data, we'll be able to do more refined market research. And ultimately, as we may propose a REMS, this is something that is going to be achieved through interactions the sponsor with FDA.
So all of this is subject to still a great deal of uncertainty until we have the data around which it's based. But we do have certain expectations as we have seen REDWOOD data as we've seen FOREST data. And as we've understood what's behind the REMS for the other cardiac myosin inhibitor, we have a view to what might ultimately be enabling of a lesser REMS, but that's still quite speculative, as you can imagine, at this point in time. Andrew, can you speak to how you've approached this from the market research standpoint?
Andrew M. Callos
Sure. So I guess there's 2 important things to understand. One is we probably won't have that much clarity in terms of exactly what a REMS program is going to look like early in the review process. That's something that we proposed to the FDA. But relative to our patient support services, independent of what the REMS will look like. There are certain elements of patient support we're going to offer.
So, we know we're going to offer things like patient assistance and [co-paper]. We'll look at echo reimbursement. We do -- we'll help with benefits verification, education on disease states. So there are certain things that we know around minimum and that we're going to do. There's other things that based on the complexity of the REMS that we'll do as well.
Our assumption going into the planning, is that we're going to assume a complex REMS with all elements, and it's a lot easier for us to simplify or back down from that once the REMS program comes into view, because when it does come into view, it's a negotiation as you're negotiating a label near the end, and we would not have enough time to react. So hopefully, that gives you a sense of how we're thinking about it.
Robert I. Blum
And just to add one more comment. If you read the summary basis of approval, there's a lot that one can learn about what the FDA was seeking to accomplish in putting in place the REMS program that does exist today. And we'll obviously be conditioned based on that prior knowledge to know what we need to glean from the evidence from FOREST and SEQUOIA in order to hopefully enable something that is different. But ultimately, that's something that comes down the road, following the acceptance and the review of a new drug application.
Operator
And our next question will come from Srikripa Devarakonda from Truist Securities.
Srikripa Devarakonda
And really looking forward to the data in about a couple of months, hopefully, less than that. I have a question about MAPLE trial. You talked about enrolling patients that are naive to therapy as well as those who were on background therapy, but withdrew from it. Can you remind me if there's any restriction in terms of how long these patients could have been on therapy, symptomatic and on standard of care? And how that featured into how the trial was powered?
Robert I. Blum
Very good questions. I'll turn to Fady, please.
Fady Ibraham Malik
I'll ask Stuart to answer since he discussed MAPLE in his section. But in general, patients could have been on beta blockers for any length of time as long as they could be withdrawn, they were considered in certain classes. And depending on the length of time, I'll let Stuart elaborate, please.
Stuart Kupfer
Yes. Thank you for the question. The concept here was to evaluate aficamten as first line use or as an optional monotherapy for patients who have been treated with standard of care for, let's say, a number of years. And so, we sort of subgroup these patients into one at either naive to beta blocker therapy or no longer receive in beta blocker therapy or on beta blocker for a short period of time versus those who have been treated beta blockers or standard of care for more than a year.
And that's sort of the breakdown and the strategy for evaluating aficamten monotherapy, as first line versus, again, a possibly a superior option versus standard of care as the aficamten monotherapy for patients who have been on standard of care for an extended period of time. So the study is designed, of course, to evaluate the potential for superiority of aficamten monotherapy versus beta blocker monotherapy in either of those subgroups of patients.
Operator
Our next question will come from Jeff Hung from Morgan Stanley.
Hannah Lynne Latimer
This is Hannah on for Jeff. You mentioned previously that physicians have indicated their interest and excitement in aficamten. We want to ask you either your reader to-date or any feedback that you received, what aspects of aficamten profile is the physicians may be finding most compelling?
Robert I. Blum
So Andrew, may I ask you to respond to that, please?
Andrew M. Callos
Sure. So with our market research when we put an aspirational profile in front of physicians. The things that they mentioned most is excited about are preservation of LVEF function. Obviously, which is the safety element, change in New York Heart class or improvement going from a 3 to a 2 or 3 to a 1, 2 to a 1 as an example, change in KCCQ and limited DDIs that really don't need to be monitored relative to dosing. Those are the things they mentioned that are most would drive their preference for aficamten.
Operator
Our next question will come from Yasmeen Rahimi from Piper Sandler.
Yasmeen Rahimi
I guess, with data expected late December and you guys entering a quiet period, I guess, December 4. Like could you maybe highlight to us what is your definition of late December? And then secondly, just maybe comment on how has been this data cleaned up as you guys have been collecting it? Or is it just like do you start like cleaning up the data as soon as things get locked out in early December? I appreciate if you could taxable to me?
Robert I. Blum
Sure. So I hope this can be helpful, but please understand, as Fady shared with you, while nearly all of the patients have completed their maintenance phase, not all of them have, and there's still some additional visits that must occur from, which data collection still must follow in order to be enabling of database lock. So while we're in the very late innings of this project, it's not yet done.
So we can't be as precise as you might like in asking the question, about what do we mean by late December. What we mean is it's going to be in December whether that's towards -- if we thought it was early December, we would have said so. Late December probably means it's, as you can imagine, weeks into the month and that's ultimately going to be defined by how quickly can, we get two database lock and the enabling of analysis.
It's not uncommon where in a study like this, it would typically take 4 to 6 or more weeks to go from database lock to tables, listings and figures from which one could distill top line results. We're going to try to do that faster and as fast as we can, subject to what are still data to be collected. To this point in time, we feel very good about where we are with data collection, enabling of database lock and analysis. And I hope that's helpful to your question.
Operator
Our next question will come from Charles Duncan from Cantor.
Charles Cliff Duncan
Congrats on the progress by you and the team. I have a couple of quick ones. A lot of great questions asked on SEQUOIA. But I did want to ask about the baseline data with regard to certain geographies and an interaction. I guess I'm wondering, when you think about all the patients that are from China versus Europe or Israel, are there any, call it, phenotypic or, call it, behavioral differences that you think may impact, call it, the read-through from China versus Israel or Europe in terms of exercise capacity.
Robert I. Blum
Good question. And I'll say I've been myself engaging with our colleagues to understand what could be accomplished for our making this a truly international registrational study and what can we learn from prior studies and what do we know? So I'll ask Fady to speak specifically to your question.
Fady Ibraham Malik
I think with regards to exercise performance, you're an athlete. If you look at our Olympic level athletes, you see they come from all over the world and performance can be seen in all those populations at an extremely high level. So similarly, I think in studies like this, we have the opportunity to see improvements in exercise performance across the board.
I'm pleased to really buy the quality of the data that we've received from all of those regions. We have experience in GALACTIC, for instance, in terms of response to omecamtiv mecarbil in all of those regions. And the response to cancer was quite strong, particularly in China, in fact. So I don't have any concerns at the moment with regards to regional variability. Obviously, we'll see when the data emerge.
Robert I. Blum
Charles, just to add, if your question is, in any way, tied to, is there additional risk for the fact that we're enrolling in some of those regions. I hope you can draw comfort from the fact that as Fady has pointed out, we're quite comfortable with the integrity of the data, the absence of missing data, the standard deviation and those things that ultimately read on statistics. So those are things that we continually monitor, and we're quite pleased with where we sit.
Charles Cliff Duncan
Yes. That actually answers both parts of the question, both in terms of at the patient level, but at the clinical site level. Let me ask you one last question. If you could (inaudible) 1.00.04, Robert. When you think about the vision of becoming a high-growth specialist-focused cardiovascular company, what are the analogs that you look to really be able to define success in the next couple of years?
Robert I. Blum
I don't foresee that there's really an analog in biopharma today, a company that is a specialty cardiovascular company. Obviously, there are specialty companies in other therapeutic categories, like in the areas of CNS, for instance. But what we are focused towards in the build-out of our pipeline and corporate development strategies are those kinds of opportunities that are directed to concentrated customer segments.
Where there would be both pricing and payer leverage where there's limited sales and marketing infrastructure required to get to a high yield, high return on investment strategy. And we don't think the other predecessor cardiology companies in the biopharma space have those advantages in order to be able to compete effectively.
We think they do exist in those markets and for those programs where our science directed to cardiac muscle lends itself to a new business model in the biopharma space and one for which we do believe there are elements that translate to maximizing shareholder value. So I hope that answers your question.
Charles Cliff Duncan
Yes it does. You've been a good student of the history of the industry. So I appreciate you providing your perspectives.
Operator
And our next question will come from Roanna Ruiz from Leerink Partners.
Roanna Clarissa H. Ruiz
So a quick one from me. I was curious if you could talk a bit more about the clinical meaningfulness of the 99.5% of monitoring echoes that did not need dose reductions in the FOREST data? And how does it actually compare to what physicians are seeing in clinical practice today with mavacamten?
Robert I. Blum
We'll address that, but I hope you'll understand if we don't make a comparative statement to mavacamten. But Fady, could I ask you to take that?
Fady Ibraham Malik
Sure. I think the reason we made that point, like I know the reason we made that point in terms of the number of echoes the number that don't require a change in management is to give some flavor to what the burden of monitoring it. If you do a test to monitor for something and it only has a meaningful outcome in less than 0.5% of the measurements that you do. You have to ask yourself, are you appropriately deploying resources in a way that is efficient and are there better ways to deploy those resources that can maintain the same degree of safety.
But not necessarily burden the system quite as heavily. So, I think incumbent on us to understand what the determinants are of those very infrequent events, how do, we anticipate them and to eliminate what our 99% of tests that have no clinical impact, but cost the system a lot in terms of resources, time and money. So I think that's ultimately why we made those points in our presentation.
Operator
And our next question will come from Justin Kim from Oppenheimer & Co.
Justin Alexander Kim
Sorry, I may have joined a little bit late, but I just had a quick question on the -- I guess, the SEQUOIA study and inclusion of patients who are refractory to SRT, just because of, I guess, the young women experience was presented a few weeks back, curious like if that experience would be similar to what we saw in EXPLORER? And any color there?
Robert I. Blum
So, I think I just want to make sure that we're using the right language. I don't know that refractory to SRT is the right way to put it. What we were pointing out was those patients who were eligible for SRT pretreatment versus post treatment. But maybe, Fady, you could speak to that.
Fady Ibraham Malik
Yes. No, that's right. These patients meet the criteria for SRT, which is that they have a New York Heart Association class of 3 or more, and that they have a gradient of 50 or more. So in FOREST, we, a couple of weeks ago, looked again at the percentage of those patients who remained eligible for SRT once they started aficamten treatment and only about 10% of them met those criteria after therapy, where of the ones that had met at the time of therapy. So, we're not necessarily inclusive of patients that are refractory to SRT. They just meet the criteria for SRT.
Justin Alexander Kim
Okay. I guess maybe just a clarification. I think there were patients who had residual gradients following surgery. And just wondering if the study includes those patients here, just given that these patients do benefit have been shown to benefit?
Robert I. Blum
Yes. No. And patients that had septal reduction therapy is an exclusion for this particular trial for SEQUOIA.
Justin Alexander Kim
Okay. Great. And maybe as a segue, I mean, just on the FOREST presentation, is there a sort of natural timing for the HCM cohort and when we might be able to see any added long-term treatment there?
Robert I. Blum
And with regards to FOREST. Yes. I mean I think what we want to see is the NCM cohort to age a little bit so that we have about at least 6 months to a year's worth of follow-up before we report those data. So you'll probably see them in 2024.
Justin Alexander Kim
Okay. We'll look forward to that ICC or ACC.
Operator
And I am showing no further questions from our phone line. I'd now like to turn the conference back over to Robert Blum, President and CEO, for any closing remarks.
Robert I. Blum
Thank you, operator, and thanks very much to everybody for joining us on this call today. We covered a lot of ground. So I won't try to synthesize or summarize that other than to say, we do look forward to the results from SEQUOIA-HCM and top lining them later in this quarter, in late December. We thank you for your continued support, your interest in Cytokinetics. And operator, with that, we can now conclude the call.
Operator
Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone, have a great day.
